Algeta’s fatal lure

Algeta ASA says the calcium-like properties of its intravenously delivered pharmaceutical preparation of radium-223 enables the radionuclide to act like a targeted chemotherapeutic to selectively destroy bone metastases with limited toxicity. Last week, the company presented data showing that Alpharadin significantly improved survival in a Phase II trial in prostate cancer